Synlogic (SYBX) Reports Q3 Loss of $0.43, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates
November 13, 2018 4:05 PM ESTAdvancement of SYNB1891, the first Synthetic Biotic immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019
Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019
Management to host conference call and webcast at 5:00 pm ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc. (Nasdaq: SYBX), a... More



